Bank of America’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-95,126
| Closed | -$3.58M | – | 8424 |
|
|
2021
Q1 | $3.58M | Buy |
95,126
+81,931
| +621% | +$2.04M | ﹤0.01% | 3729 |
|
|
2020
Q4 | $224K | Sell |
13,195
-3,428
| -21% | -$42.9K | ﹤0.01% | 5528 |
|
|
2020
Q3 | $78K | Sell |
16,623
-4,340
| -21% | -$22K | ﹤0.01% | 5807 |
|
|
2020
Q2 | $128K | Buy |
20,963
+3,274
| +19% | +$13.5K | ﹤0.01% | 5546 |
|
|
2020
Q1 | $40K | Sell |
17,689
-6,700
| -27% | -$28.4K | ﹤0.01% | 5955 |
|
|
2019
Q4 | $112K | Sell |
24,389
-7,482
| -23% | -$29.6K | ﹤0.01% | 5951 |
|
|
2019
Q3 | $123K | Sell |
31,871
-3,581
| -10% | -$19.6K | ﹤0.01% | 5940 |
|
|
2019
Q2 | $214K | Sell |
35,452
-99,496
| -74% | -$951K | ﹤0.01% | 5584 |
|
|
2019
Q1 | $1.81M | Buy |
134,948
+22,024
| +20% | +$251K | ﹤0.01% | 4069 |
|
|
2018
Q4 | $1.05M | Buy |
112,924
+16,299
| +17% | +$194K | ﹤0.01% | 4363 |
|
|
2018
Q3 | $1.35M | Sell |
96,625
-4,243
| -4% | -$63.1K | ﹤0.01% | 4287 |
|
|
2018
Q2 | $1.59M | Buy |
100,868
+336
| +0.3% | +$5.86K | ﹤0.01% | 4151 |
|
|
2018
Q1 | $1.73M | Buy |
100,532
+54,822
| +120% | +$1.07M | ﹤0.01% | 3989 |
|
|
2017
Q4 | $1M | Buy |
45,710
+18,337
| +67% | +$590K | ﹤0.01% | 4490 |
|
|
2017
Q3 | $1.12M | Buy |
27,373
+12,339
| +82% | +$387K | ﹤0.01% | 4438 |
|
|
2017
Q2 | $452K | Sell |
15,034
-3,524
| -19% | -$110K | ﹤0.01% | 4944 |
|
|
2017
Q1 | $671K | Buy |
18,558
+1,025
| +6% | +$45.2K | ﹤0.01% | 4691 |
|
|
2016
Q4 | $879K | Buy |
17,533
+4,339
| +33% | +$228K | ﹤0.01% | 4438 |
|
|
2016
Q3 | $692K | Sell |
13,194
-1,253
| -9% | -$59.8K | ﹤0.01% | 4403 |
|
|
2016
Q2 | $598K | Buy |
14,447
+11,858
| +458% | +$516K | ﹤0.01% | 4539 |
|
|
2016
Q1 | $105K | Sell |
2,589
-2,262
| -47% | -$77.7K | ﹤0.01% | 5465 |
|
|
2015
Q4 | $201K | Buy |
4,851
+4,549
| +1,506% | +$152K | ﹤0.01% | 5376 |
|
|
2015
Q3 | $5K | Sell |
302
-23,787
| -99% | -$511K | ﹤0.01% | 6765 |
|
|
2015
Q2 | $598K | Buy |
24,089
+24,031
| +41,433% | +$535K | ﹤0.01% | 4556 |
|
|
2015
Q1 | $1K | Sell |
58
-2,042
| -97% | -$51.5K | ﹤0.01% | 6900 |
|
|
2014
Q4 | $57K | Sell |
2,100
-885
| -30% | -$15.2K | ﹤0.01% | 6269 |
|
|
2014
Q3 | $35K | Buy |
+2,985
| New | +$37.7K | ﹤0.01% | 6749 |
|
|
2014
Q2 | – | Sell |
-13
| Closed | – | – | 8295 |
|
|
2014
Q1 | $0 | Buy |
+13
| New | +$221 | ﹤0.01% | 8219 |
|
Bank of America's FPRX Position: Q2 2021 in Review
Bank of America sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 95,126 shares — an estimated $3.58M sold.
Bank of America first reported a position in FPRX in Q1 2014 and held it in 28 quarters. The position peaked at $3.58M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Bank of America reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Bank of America sold 95,126 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $3.58M.
- Bank of America first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 28 quarters.
- Bank of America's Five Prime Therapeutics, Inc. position peaked at $3.58M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Bank of America's 13F filing for Q2 2021, filed 16 Aug 2021.